University of Catania
Follow us
Search

HA Carnosina

Progetto di sviluppo del principio attivo HA Carnosina e del suo utilizzo sotto forma di farmaco per la cura delle patologie osteoarticolari e dispositivo medico per la riparazione tissutale
Classification: 
national research
Programme: 
PON Ricerca e Innovazione 2014-2020
Call: 
Decreto MISE- H2020 del 1 giugno 2016, recante l'intervento del Fondo per la crescita sostenibile in favore di progetti di ricerca e sviluppo negli ambiti tecnologici identificati dal Programma quadro comunitario "Orizzonte 2020" da realizzarsi attraverso l'utilizzo delle risorse del Programma Operativo Nazionale "Imprese e Competitività" 2014 - 2020 FESR nelle regioni meno sviluppate e nelle regioni in transizione del territorio nazionale
Main ERC field: 
Life Sciences
Unict role: 
Co-proposer
Duration (months): 
36
Start date: 
Monday, April 3, 2017
End date: 
Friday, April 2, 2021
Total cost: 
€ 3.614.848,88
Unict cost: 
€ 267.543,74
Coordinator: 
Fidia Farmaceutici S.p.A.
Principal investigator in Unict: 
Agata Graziella Copani
University department involved: 
Department of Drug Sciences
Participants: 

EUROFARM S.p.A.

Abstract

The aim of the project is the research and development of a new product: the bio-conjugate of hyaluronic acid (HA) with carnosine, as a pharmaceutical ingredient. During the project, industrial research and experimental development will be carried out with the aim of producing and characterizing the new active ingredient and developing at least one formulation (oral or intra-articular) for the treatment of osteoarticular pathologies and a medical device for the treatment of skin ulcers. In addition to the chemical-physical and pharmacological characterization, to the study of the molecule's action mechanism and its effectiveness in the treatment of the above mentioned pathologies, all preclinical activities in GLP, of in vivo toxicity, and the validation of the production process will be carried out. according to the CGMP necessary for obtaining the production authorization of the new pharmaceutical active ingredient.